Saturday, November 26, 2022

Development of the next generation of microscopes

Peer-Reviewed Publication

UIT THE ARCTIC UNIVERSITY OF NORWAY

Florian Ströhl 

IMAGE: : FLORIAN STRÖHL INITIALLY GOT THE IDEA A FEW YEARS AGO. "I BUILT THE VERY FIRST PROTOTYPE BY HAND. IT TOOK FOREVER, SINCE I HAD TO DO EVERYTHING MANUALLY. THEREFORE, I WAS VERY RELIEVED WHEN IT YIELDED RESULTS AND PROVIDED GREAT IMAGES," SAYS STRÖHL. view more 

CREDIT: KJETIL RYDLAND/UIT

To observe living cells through a microscope, a sample is usually squeezed onto a glass slide. It then lies there calmly and the cells are observable. The disadvantage is that this limits how the cells behave and it only produces two-dimensional images. 

Researchers from UiT The Arctic University of Norway and the University Hospital of North Norway (UNN) have now developed what they are referring to as the next generation microscope. The new technology can take pictures of much larger samples than before, while living and working in a more natural environment. 

A major development

The technology provides 3D images where researchers can study the smallest details from several angles, clearly and visibly, sorted into different layers and all layers are in focus.

3D microscopes do already exist, but they work slowly and give poorer results. The most common type works by recording pixel after pixel in series, which are then assembled into a 3D image. This takes time and often they can't handle more than 1-5 shots a minute. It's not very practical if what you're going to photograph something that moves. 

“With our technology, we can manage around 100 full frames per second.  And we believe it is possible to increase this number. This is just what we have demonstrated with our prototype," says Florian Ströhl, researcher at UiT. 

The new microscope is a so-called multifocus microscope, which provides completely clear images, sorted into different layers, where you can study the cells from all angles.

“It’s a big deal. The fact that we manage to get all this in one take, it is a huge development," says Ströhl. 

Can see behind objects

Ströhl explains that we are not talking about 3D in the form most of us know it. 
While in a traditional 3D image you will be able to perceive some kind of depth, with the new technology you are also be able to see behind objects.

Ströhl uses an example where you see a jungle scene in 3D at the cinema.

“In a normal 3D image, you can see that the forest has a depth, that some leaves and trees are closer than others. With the same technology used in our new 3D microscope, you are also able to see the tiger hiding behind the bushes. You are able to see and study several layers independently," says Ströhl. 

Now you do not use a microscope to look for tigers in the jungle, but for researchers this can be an important tool when looking for answers in the minutest details. 

Studying heart cells – while they beat

Ströhl has collaborated with researchers and doctors from the University Hospital of North Norway (UNN) in the development of this technology. 

Among other things, they work to understand and develop better treatment methods for various heart diseases. 

Studying a living human heart is challenging, both for technical reasons and not least for ethical reasons. Thus, researchers have used stem cells that are manipulated so that they mimic heart cells. 
In this way, they can grow organic tissue that behaves as it would in a human heart, and they can study and test this tissue to understand more about what is happening.

This tissue is almost like a small lump of live meat, about 1 cm in size. This makes for a very demanding test situation, where heart cells beat and are in constant motion along it the fact that the sample is too large to study with traditional microscopes.
The new microscope handles this well.

“You have this pumping lump of meat in a bowl, which you want to take microscope pictures of. You want to view at the very smallest parts of this, and you want super high resolution. We have achieved this with the new microscope," says Ströhl. 

Formula 1 division

Kenneth Bowitz Larsen heads a large laboratory with advanced microscopes that are used by all the research groups at the Faculty of Health at UiT. 
He has tested this new microscope, and is optimistic.

"The concept is brilliant, the microscope they have built does things that the commercial systems do not," Larsen explains. 
The laboratory he heads mainly uses commercial microscopes from suppliers such as Zeiss, Nikon, etc. 

“Then we also collaborate with research groups like the one Florian Ströhl represents. They build microscopes and test optical concepts, they are in a way like the formula 1 division of microscopy," Larsen says.
Larsen has great faith in the new microscope Ströhl has created.

The commercial microscopes must be usable for all kinds of possible samples, while the microscope Ströhl has developed is more tailored to a specific task. 

“It is very photosensitive, and it can depict the specimen in various focuses. It can work its way through the sample and you can view both high and low. And it happens so fast that it can practically be seen in real time. It's an extremely fast microscope," Larsen says.

According to Larsen, the tests so far show that this works well, and he believes this type of microscope can eventually be used on all types of samples where you look at living things that move.

He also sees another advantage with the speed of this microscope.

“Bright lights are not kind to cells. Since this microscope is so fast, it exposes the cells to much shorter illumination and is therefore more gentle," he explains.

The technology is patented

The prototype of the microscope works and is operational. The researchers are currently working on creating an upgraded version that is easier to use, so that more people are able to operate and use the microscope. 

The researchers have also applied for a patent and are also looking for industrial partners who will develop this into a microscope that will be available for sale.

In the meantime, the prototype will be made available to local partners who can benefit from the new technology.

"We will also offer it to others in Norway, if they have particularly demanding samples that they want examined," says Ströh

Florian Ströhl initially got the idea a few years ago. "I built the very first prototype by hand. It took forever, since I had to do everything manually. Therefore, I was very relieved when it yielded results and provided great images," says Ströhl.

CREDIT

Kjetil Rydland/UiT

Lung cancer screening dramatically increases long-term survival rate

Reports and Proceedings

THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE

New York, NY (November 22, 2022) — Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.

The results show that patients diagnosed with lung cancer at an early stage via CT screening have a 20-year survival rate of 80 percent. The average five-year survival rate for all lung cancer patients is 18.6 percent because only 16 percent of lung cancers are diagnosed at an early stage. More than half of people with lung cancer die within one year of being diagnosed, making it the leading cause of cancer deaths. By the time symptoms appear, it is often too late.

The findings are the latest to demonstrate the importance of routine and early screening in detecting cancers when they are small enough to be cured by surgical removal. Unfortunately, fewer than 6 percent of the people eligible for screening get it.

“While screening doesn’t prevent cancers from occurring, it is an important tool in identifying lung cancers in their early stage when they can be surgically removed,” said the study’s lead author, Claudia Henschke, PhD, MD, Professor of Diagnostic, Molecular and Interventional Radiology and Director of the Early Lung and Cardiac Action Program at the Icahn School of Medicine at Mount Sinai in New York. “Ultimately, anyone interested in being screened needs to know that if they are unfortunate enough to develop lung cancer, it can be cured if found early.”

While treatments of more advanced cancers with targeted therapy and immunotherapy have come a long way, the best tool against lung cancer deaths is early diagnosis through low-dose CT screening before symptoms occur, according to the study authors.

“Symptoms occur mainly in late-stage lung cancer,” Dr. Henschke said. “Thus, the best way to find early-stage lung cancer is by enrolling in an annual screening program.”

The U.S. Preventive Services Task Force recommends annual lung cancer screening with low-dose CT in adults aged 50 to 80 years who have a 20 pack-year smoking history, which equals at least a pack a day for 20 years, and who currently smoke or have quit within the past 15 years.

The study tracked the 20-year survival rate of 1,285 patients who were screened in the International Early Lung Cancer Action Program (I-ELCAP) and who were later diagnosed with early-stage lung cancer. While the overall survival of the participants was 80 percent, the survival rate for the 139 participants with nonsolid cancerous lung nodules and the 155 participants with nodules that had a partly solid consistency was 100 percent. For the 991 participants with solid nodules, the survival rate was 73 percent. For participants with Stage 1A cancers that measured 10 mm or less, the 20-year survival rate was 92 percent.

Dr. Henschke and colleagues have been studying the effectiveness of cancer detection with low-dose CT screening for years. The efforts of the researchers to advance CT screening for early lung disease led to the creation of the I-ELCAP. Started in 1992, this multi-institution, multi-national research program has enrolled more than 87,000 participants from over 80 institutions.

In 2006, the researchers identified a 10-year survival rate of 80 percent for the patients whose cancer was identified by CT screening. For this study, they looked at 20-year survival rates.

“What we present here is the 20-year follow-up on participants in our screening program who were diagnosed with lung cancer and subsequently treated,” Dr. Henschke said. “The key finding is that even after this long a time interval they are not dying of their lung cancer. And even if new lung cancers were found over time, as long as they continued with annual screening, they would be OK.” 

Co-authors are David F. Yankelevitz, MD, Director of the Lung Biopsy Service at Icahn Mount Sinai; Daniel M. Libby, MD, Professor of Medicine at Weill Cornell Medical Center; James Smith, MD, Clinical Professor of Medicine at Weill Cornell Medical Center; Mark Pasmantier, MD, Weill Cornell Medical Center, and Rowena Yip, MPH, Senior Biostatistician at the I-ELCAP at Icahn Mount Sinai.  

 

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.

Tufts University researchers find link between foods scored higher by new nutrient profiling system and better long-term health outcomes


Diets deemed better by Friedman School’s Food Compass associated with lower risk for disease and death

Peer-Reviewed Publication

TUFTS UNIVERSITY

The idea that what we eat directly affects our health is ancient; Hippocrates recognized this as far back as 400 B.C. But, identifying healthier foods in the supermarket aisle and on restaurant menus is increasingly challenging. Now, researchers at the Friedman School of Nutrition Science and Policy at Tufts have shown that a holistic food profiling system, Food Compass, identifies better overall health and lower risk for mortality.  

In a paper published in Nature Communications on November 22, researchers assessed whether adults who ate more foods with higher Food Compass scores had better long-term health outcomes and found that they did.

Introduced in 2021, Food Compass provides a holistic measure of the overall nutritional value of a food, beverage, or mixed meal. It measures 9 domains of each item, such as nutrient ratios, food-based ingredients, vitamins, minerals, extent of processing, and additives. Based on scores of 10,000 commonly consumed products in the U.S., researchers recommend foods with scores of 70 or above as foods to encourage; foods with scores of 31-69 to be eaten in moderation; and anything that scores 30 or below to be consumed sparingly. For this new study, Food Compass was used to score a person’s entire diet, based on the Food Compass scores of all the foods and beverages they regularly consume.

“A nutrient profiling system is intended to be an objective measure of how healthy a food is. If it’s achieving its purpose, then individuals who eat more foods with higher scores should have better health,” said Meghan O’Hearn, a doctoral candidate at the Friedman School and the study’s lead author.

For this validation study, researchers used nationally representative dietary records and health data from 47,999 U.S. adults aged 20-85 who were enrolled between 1999-2018 in the National Health and Nutrition Examination Survey (NHANES). Deaths were determined through linkage with the National Death Index (NDI).

Overall, researchers found that the mean Food Compass score for the diets of the nearly 50,000 subjects was only 35.5 out of 100, well below ideal. “One of the most alarming discoveries was just how poor the national average diet is,” said O’Hearn. “This is a call for actions to improve diet quality in the United States.”

When people’s Food Compass diet scores were assessed against health outcomes, multiple significant relationships were seen, even adjusting for other risk factors like age, sex, race, ethnicity, education, income, smoking, alcohol intake, physical activity, and diabetes status. A higher Food Compass diet score was associated with lower blood pressure, blood sugar, blood cholesterol, body mass index, and hemoglobin A1c levels; and lower prevalence of metabolic syndrome and cancer. A higher Food Compass diet score was also associated with lower risk of mortality: for each 10-point increase, there was a 7 percent lower risk of death from all causes.

“When searching for healthy foods and drinks, it can be a bit of a wild west,” said Dariush Mozaffarian, Jean Mayer Professor of Nutrition and dean for policy at the Friedman School. “Our findings support the validity of Food Compass as a tool to guide consumer decisions, as well as industry reformulations and public health strategies to identify and encourage healthier foods and beverages.”

Compared to existing nutrient profiling systems, Food Compass provides a more innovative and comprehensive assessment of nutritional quality, researchers say. For example, rather than measuring levels of dietary fats, sodium, or fiber in isolation, it takes a more nuanced and holistic view, evaluating the ratio of saturated to unsaturated fat; sodium to potassium; and carbohydrate to fiber.

Food Compass also boosts scores for ingredients shown to have protective effects on health, like fruits, non-starchy vegetables, beans and legumes, whole grains, nuts and seeds, seafood, yogurt, and plant oils; and lowers scores for less healthful ingredients like refined grains, red and processed meat, and ultra-processed foods and additives.

Researchers designed Food Compass with the ever-evolving field of nutrition science in mind, and their multidisciplinary team—comprised of researchers with expertise in epidemiology, medicine, economics, and biomolecular nutrition—will continue to evaluate and adapt the tool based on the most cutting-edge nutrition research.

“We know Food Compass is not perfect,” said Mozaffarian. “But, it provides a more comprehensive, holistic rating of a food’s nutritional value than existing systems, and these new findings support its validity by showing it predicts better health.”

These findings are timely given the release of the new U.S. National Strategy on Hunger, Nutrition and Health. One pillar of this strategy is to “empower all consumers to make and have access to healthy choices” through measures such as updating food labeling and making it easier to interpret, creating healthier food environments, and creating a healthier food supply.

“This study further validates Food Compass as a useful tool for defining healthy foods. We hope the Food Compass algorithm—publicly available to all—can help guide front-of-pack labeling; procurement choices in workplace, hospital, and school cafeterias; incentive programs for healthier eating in healthcare and federal nutrition programs; industry reformulations; and government policies around food,” said O’Hearn.  

Researchers plan to work on a simplified version that requires fewer nutrient inputs, as well as versions tailored to specific conditions such as diabetes and pregnancy or to other nations’ populations. The research team is also interested in adding Food Compass domains based on other aspects of foods, such as environmental sustainability, social justice, or animal welfare.

“We look forward to continuing to find ways to improve the Food Compass system, and to get it to more users to help clear up confusion about healthier choices,” said Mozaffarian.

Research reported in this article was supported by the National Institutes of Health’s National Heart, Lung, and Blood Institute under award number 2R01HL115189 and Vail Innovative Global Research. Complete information on authors, funders, and conflicts of interest is available in the published paper.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

Challenging guidelines on pregnancy interval following miscarriage or abortion

Study reviews over 72,000 Norwegian births over eight years

Peer-Reviewed Publication

PLOS

Challenging guidelines on pregnancy interval following miscarriage or abortion 

IMAGE: RESEARCHERS REVIEW GUIDELINES ON PREGNANCY INTERVAL FOLLOWING MISCARRIAGE OR ABORTION. view more 

CREDIT: PIXABAY, PEXELS (CC0, HTTPS://CREATIVECOMMONS.ORG/PUBLICDOMAIN/ZERO/1.0/)

Conception within three months of a miscarriage or an abortion is not associated with increased risks of adverse pregnancy outcomes, according to new research publishing November 22nd in the open access journal PLOS Medicine. The study suggests that, contrary to current advice, women could attempt pregnancy after a previous miscarriage or induced abortion without elevated perinatal risks and reassures those who want to try again sooner than guidelines recommend.

The World Health Organization recommends waiting six months after miscarriage or abortion before becoming pregnant again to avoid complications in the next pregnancy, yet evidence for this is scarce. Gizachew Tessema of the Curtin School of Population Health, Australia, and colleagues conducted a cohort study with a total of 49,058 births following miscarriage and 23,707 births following abortion in Norway between 2008-2016. They looked at six adverse outcomes: preterm birth, spontaneous preterm birth, small for gestational age, large for gestational age, preeclampsia and gestational diabetes.

Compared with waiting 6-11 months after miscarriage, there were lower risks of small for gestational age for babies conceived in less than six months and a lower risk of gestational diabetes in women conceiving in under three months. Following abortion there was a slight but non-significant increased risk of small for gestational age for conception in less than three months compared with 6-11 months but the risk of large for gestational age was lower in the group with an interpregnancy interval of 3-5 months.

There was no evidence of higher risks of adverse pregnancy outcomes among women with an IPI of greater than 12 months after miscarriages or induced abortions, with the exception of a modest increased risk of gestational diabetes. The authors acknowledge that the study was limited in that it lacked information on potential confounders, including pregnancy intention and health seeking behavior. Additionally, the data only included miscarriages recorded through the healthcare system.

The findings do not support current guidelines to wait six months after miscarriage or abortion, and suggest a need to review these guidelines and provide up to date, evidence based, recommendations for women.

The authors add, “Based on this study and others, we called for a review of the existing World Health Organization recommendations for pregnancy spacing following pregnancy loss.”

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004129

Citation: Tessema GA, Håberg SE, Pereira G, Regan AK, Dunne J, Magnus MC (2022) Interpregnancy interval and adverse pregnancy outcomes among pregnancies following miscarriages or induced abortions in Norway (2008–2016): A cohort study. PLoS Med 19(11): e1004129. https://doi.org/10.1371/journal.pmed.1004129

Author Countries: Australia, Norway, United States

Funding: see manuscript

The current emergence of monkeypox: The recurrence of another smallpox?

Peer-Reviewed Publication

COMPUSCRIPT LTD

https://doi.org/10.1016/j.bsheal.2022.09.004

 

Since its first confirmation in London on 12 May 2022, many monkeypox cases have been reported worldwide. Noticeably, the epidemiology, pathology, and clinical features of the current emergence have been compared to those of smallpox, a severe contagious disease historically epidemic worldwide for nearly 3,000 years. However, some characteristics of the present outbreak differed from those of previous monkeypox outbreaks. The authors of this article consider if this emergence of monkeypox could cause another global pandemic similar to smallpox or influenza or if it is only the re-emergence of a new strain. To address these questions, they reviewed its virology, transmission, clinical characteristics, experimental diagnosis, and prevention and intervention.

 

Keywords: Monkeypox, Epidemiology, Clinical characteristics, Vaccine, Drugs, Biosafety

 

# # # # # #

 

Biosafety and Health is sponsored by the Chinese Medical Association, managed by National Institute for Viral

Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC).

For more information, please visit https://www.journals.elsevier.com/biosafety-and-health

Editorial Board: https://www.sciencedirect.com/journal/biosafety-and-health/about/editorial-board

Biosafety and Health is available on ScienceDirect (https://www.sciencedirect.com/journal/biosafety-and-health).

Submissions to Biosafety and Health may be made using Editorial Manager®

(https://www.editorialmanager.com/bsheal/default.aspx).

CiteScore: 4.8

ISSN 2590-0536

 

# # # # # #

 

Article reference: Tianyu Lu, Zongzhen Wu, Shibo Jiang, Lu Lu, Huan Liu, The current emergence of monkeypox: The recurrence of another smallpox?, Biosafety and Health, 2022, ISSN 2590-0536, https://doi.org/10.1016/j.bsheal.2022.09.004

The market reacts to stocks purchased by US senators, with little effect when lawmakers sell stocks

New research in the Strategic Management Journal finds abnormal returns are higher if the senator has direct jurisdiction over the firm.

Peer-Reviewed Publication

STRATEGIC MANAGEMENT SOCIETY

Stock purchases by U.S. Senate members generate abnormal returns, according to a study of purchases made by the politicians between 2012 and 2020. The findings, published in the Strategic Management Journal, also suggest that abnormal returns are higher if the senator has direct jurisdiction over the firm by way of committee assignments, along with an increase in abnormal returns if the firm is tied to the senator via lobbying-sponsored legislation and political action committee contributions. However, they found little evidence that stocks traded by Congress members outperform the market. 

“Contrary to investors’ perception, we find that stocks sold and purchased by senators experienced negative abnormal returns over the six- to 12-month period following the transaction date,” says study co-author Mirzokhidjon Abdurakhmonov, an assistant professor of management at the University of Nebraska-Lincoln. “Also, while the market seems to react to stock purchases by members of Congress, there was little reaction when these politicians sell their stocks.” 

Previous studies about Congress members’ stock trades focused on the overall performance of politician-traded stocks, with little attention paid to how investors perceive such trades, prompting Abdurakhmonov and his co-authors to research the topic. What they found was little evidence that stocks traded by Congress members outperform the market — and that the opposite is potentially true. Yes, the market reacts positively to the purchase of stock by a senator, but the researchers’ post-hoc analyses were unable to find a similar effect for the disclosure of stock sales by the senator. This suggests that information about senators’ stock purchases is more valuable to investors than stock sales. 

The researchers suggest that to mitigate potential sways in the market caused by politician stock trades, lawmakers' stock holdings should be limited to blind trusts or exchange-traded funds that follow broad stock market indexes and asset classes. And by tying lawmakers' wealth with broad economic indicators of the country, their personal interests would align with national interests. This would increase public trust by reducing the appearance of potential impropriety — as would a ban on trades of stocks that are directly regulated by members of bureaucracy or legislature. 

Although firms may not have direct control over if or when a senator invests in a firm, the results suggest that the connection of the firm to the legislator — by way of lobbying the senator's legislative proposals or campaign contributions — does matter. Abdurakhmonov says this makes the case for firms to aim for an expanded breadth of government, because they not only mitigate risks produced by the government, but it helps to generate positive market returns if and when legislators do invest in such firms. 

The researchers also found that — while senators were slow to comply with the Stock Trading Act of 2012 — there has been an increase in on-time disclosures: Within the sample time frame studied, most senators disclosed their stock trades within a 36-day window, and more than 90% were reported within the 45-day reporting period.

The Strategic Management Journal, published by the Strategic Management Society, is the world’s leading mass impact journal for research in strategic management.